Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265247 | 0.92 | MEN1 (0.47) | LPLLIPGHRH3CA1CA2 | |
| SCHEMBL28451270 | 0.83 | LPL (0.59) | LPLLIPGHRH3CA1CA2 | |
| Hydrochloric Acid SCHEMBL3337542 | 0.81 | LPL (0.57) | LPLLIPGHRH3CA1CA2 | |
| SCHEMBL14019814 | 0.80 | MEN1 (0.51) | HRH3MEN1KMT2A | |
| SCHEMBL2552678 | 0.80 | EBP (0.51) | HRH3CA1CA2MEN1KMT2A | |
| SCHEMBL14376647 | 0.79 | MCHR1 (0.46) | HRH3MEN1KMT2A | |
| SCHEMBL17230510 | 0.79 | TSHR (0.49) | — | |
| SCHEMBL3620117 | 0.79 | KDM4E (0.56) | HRH3MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL615299 | 0.78 | TSHR (0.56) | MEN1KMT2A | |
| SCHEMBL1061090 | 0.77 | LPL (0.52) | LPLLIPGHRH3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398598-B1 | SULFONAMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | HITGEN INC (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-11149008-B2 | Sulfamide derivatives and preparation method and use thereof | HitGen, Inc. | 2021-10-19 | — | — | US | disclosed |
| US-20190031612-A1 | SULFAMIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HITGEN LTD. (CN) | 2019-01-31 | — | — | US | disclosed |
| EP-3398598-A1 | SULFONAMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | Hitgen Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149008-B2 | Sulfamide derivatives and preparation method and use thereof | HDAC6, HDAC1, HDAC11 | LPL 4661/4885LIPG 4372/4885HRH3 791/4885 |
| US-20190031612-A1 | SULFAMIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HDAC6, HDAC1, HDAC11 | LPL 4661/4885LIPG 4372/4885HRH3 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.